Anti-KCNH2/ ERG-1/ ERG1 monoclonal antibody
Anti-KCNH2/ ERG-1/ ERG1 antibody for FACS & in-vivo assay
Go to KCNH2/KCNH2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T20251-Ab-1/ GM-Tg-hg-T20251-Ab-2 | Anti-Human KCNH2 monoclonal antibody | Human |
GM-Tg-rg-T20251-Ab-1/ GM-Tg-rg-T20251-Ab-2 | Anti-Rat KCNH2 monoclonal antibody | Rat |
GM-Tg-mg-T20251-Ab-1/ GM-Tg-mg-T20251-Ab-2 | Anti-Mouse KCNH2 monoclonal antibody | Mouse |
GM-Tg-cynog-T20251-Ab-1/ GM-Tg-cynog-T20251-Ab-2 | Anti-Cynomolgus/ Rhesus macaque KCNH2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T20251-Ab-1/ GM-Tg-felg-T20251-Ab-2 | Anti-Feline KCNH2 monoclonal antibody | Feline |
GM-Tg-cang-T20251-Ab-1/ GM-Tg-cang-T20251-Ab-2 | Anti-Canine KCNH2 monoclonal antibody | Canine |
GM-Tg-bovg-T20251-Ab-1/ GM-Tg-bovg-T20251-Ab-2 | Anti-Bovine KCNH2 monoclonal antibody | Bovine |
GM-Tg-equg-T20251-Ab-1/ GM-Tg-equg-T20251-Ab-2 | Anti-Equine KCNH2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T20251-Ab-1/ GM-Tg-hg-T20251-Ab-2; GM-Tg-rg-T20251-Ab-1/ GM-Tg-rg-T20251-Ab-2; GM-Tg-mg-T20251-Ab-1/ GM-Tg-mg-T20251-Ab-2; GM-Tg-cynog-T20251-Ab-1/ GM-Tg-cynog-T20251-Ab-2; GM-Tg-felg-T20251-Ab-1/ GM-Tg-felg-T20251-Ab-2; GM-Tg-cang-T20251-Ab-1/ GM-Tg-cang-T20251-Ab-2; GM-Tg-bovg-T20251-Ab-1/ GM-Tg-bovg-T20251-Ab-2; GM-Tg-equg-T20251-Ab-1/ GM-Tg-equg-T20251-Ab-2 |
Products Name | Anti-KCNH2 monoclonal antibody |
Format | mab |
Target Name | KCNH2 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-KCNH2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species KCNH2/ ERG-1/ ERG1 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T20251 |
Target Name | KCNH2 |
Gene ID | 3757,16511,117018,714174,403761,101081621,539971,100064000 |
Gene Symbol and Synonyms | cerg,derg,erg,ERG-1,ERG1,H-ERG,HERG,HERG1,KCNH2,Kv11.1,LQT,LQT2,M-erg,Merg1,merg1a,merg1b,SQT1 |
Uniprot Accession | Q12809,O08962,Q9TSZ3 |
Uniprot Entry Name | KCNH2_HUMAN,KCNH2_RAT,KCNH2_CANLF |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000055118 |
Target Classification | Ion Channel |
The target: KCNH2, gene name: KCNH2, also named as ERG-1, ERG1, H-ERG, HERG, HERG1, Kv11.1, LQT2, SQT1. This gene encodes a component of a voltage-activated potassium channel found in cardiac muscle, nerve cells, and microglia. Four copies of this protein interact with one copy of the KCNE2 protein to form a functional potassium channel. Mutations in this gene can cause long QT syndrome type 2 (LQT2). Transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, May 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.